What the studies show
The outcome patients feel: more than half of treated patients gained at least one night a week off parenteral support, against under a quarter on placebo.
“The percentage of patients with a 1-day or more reduction in the weekly need for parenteral support was greater in the teduglutide group (21/39 [54%]) than in the placebo group (9/39 [23%]; P = .005).”
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS).Gastroenterology, 2012;143:1473–148186 randomised, 24 weeks. NCT00798967.
In context
Teduglutide is a 33-amino-acid analogue of glucagon-like peptide-2, approved since 2012 as Gattex in the US and Revestive in the EU for short bowel syndrome in people dependent on parenteral support. In the pivotal STEPS trial, 63% of treated patients reduced their intravenous feeding volume against 30% on placebo over 24 weeks. It is given by daily subcutaneous injection and is prescription-only everywhere LYO covers.
Teduglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Teduglutide proven to help with days free of intravenous feeding?
What studies are behind the grade?
Is Teduglutide approved for this?
Other outcomes for Teduglutide
- AReduced parenteral support in short bowel syndrome1 phase 3 RCT (STEPS, n=86, 24 wk)
- AColorectal neoplasia riskadverseLabel; approval programme
- AGastrointestinal and stoma adverse effectsadverseApproval programme
Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →